NADAC acquisition cost data for FONDAPARINUX 7.5 MG/0.6 ML SYR. This is a generic medication, typically more affordable than brand-name equivalents.
| NDC | NADAC/Unit | Effective Date | Type |
|---|---|---|---|
| 00781346595 | $57.45 | 2021-12-22 | Rx |
| 43598060910 | $57.45 | 2021-12-22 | Rx |
| 55111068010 | $57.45 | 2021-12-22 | Rx |
| 55150023210 | $57.45 | 2021-12-22 | Rx |
| 67457058406 | $57.45 | 2021-12-22 | Rx |
| 70710151606 | $57.45 | 2021-12-22 | Rx |
| 00781346595 | $57.45 | 2021-12-22 | Rx |
| 43598060910 | $57.45 | 2021-12-22 | Rx |
| 55111068010 | $57.45 | 2021-12-22 | Rx |
| 55150023210 | $57.45 | 2021-12-22 | Rx |
Generic: Fondaparinux Sodium | Manufacturer: Overall
| Year | Total Spending | Claims | Beneficiaries | Cost/Unit |
|---|---|---|---|---|
| 2019 | $24.4M | 17,284 | 4,179 | $95.46 |
| 2020 | $21.7M | 15,142 | 3,280 | $91.89 |
| 2021 | $18.1M | 14,362 | 3,145 | $80.00 |
| 2022 | $19.9M | 13,913 | 2,855 | $89.47 |
| 2023 | $19.1M | 13,028 | 2,688 | $89.56 |
| State | Total Cost | Claims | Beneficiaries |
|---|---|---|---|
| New York | $1.9M | 1,247 | 218 |
| Florida | $1.5M | 1,039 | 299 |
| Pennsylvania | $1.5M | 1,074 | 235 |
| Michigan | $1.2M | 772 | 151 |
| Massachusetts | $1.2M | 924 | 171 |
| Ohio | $1.1M | 837 | 170 |
| Texas | $968.7K | 586 | 132 |
| Indiana | $877.7K | 532 | 100 |
| California | $833.1K | 594 | 154 |
| North Carolina | $689.1K | 417 | 82 |
| Illinois | $607.7K | 561 | 111 |
| New Jersey | $584.0K | 351 | 62 |
| Tennessee | $454.6K | 304 | 62 |
| Maryland | $431.8K | 284 | 57 |
| Connecticut | $416.2K | 327 | 54 |
| Kentucky | $375.0K | 286 | 56 |
| Georgia | $363.5K | 265 | 73 |
| Virginia | $341.9K | 199 | 43 |
| Minnesota | $310.2K | 240 | 62 |
| Arizona | $299.4K | 164 | 32 |
| Colorado | $275.1K | 189 | 55 |
| Oregon | $264.4K | 203 | 48 |
| Wisconsin | $260.0K | 159 | 41 |
| Missouri | $193.1K | 130 | 26 |
| New Hampshire | $185.7K | 127 | 18 |
| Washington | $177.9K | 132 | 38 |
| Nebraska | $168.2K | 124 | 20 |
| Mississippi | $163.5K | 78 | 16 |
| Arkansas | $150.4K | 94 | 24 |
| New Mexico | $141.5K | 66 | 15 |
| Oklahoma | $134.9K | 68 | 17 |
| South Carolina | $129.3K | 80 | 26 |
| Alabama | $109.7K | 69 | 23 |
| Utah | $93.0K | 40 | N/A |
| Maine | $89.3K | 52 | 18 |
| Louisiana | $87.2K | 40 | N/A |
| Nevada | $73.7K | 39 | N/A |
| Kansas | $68.9K | 72 | 12 |
| District of Columbia | $68.6K | 35 | 11 |
| Idaho | $60.2K | 48 | N/A |
| West Virginia | $53.3K | 24 | N/A |
| Vermont | $50.5K | 31 | 13 |
| Rhode Island | $37.8K | 24 | N/A |
| Alaska | $37.1K | 14 | N/A |
| Iowa | $25.2K | 22 | N/A |
| Montana | $13.9K | 23 | N/A |
| North Dakota | $12.0K | 12 | N/A |
| Hawaii | $6.5K | 15 | N/A |
The DrugPricePeek editorial team aggregates and verifies drugs data from CMS NADAC & Medicare Part D. Every statistic on this site is cross-referenced against the official source before publication, with quarterly re-verification cycles.
Read our full methodology or contact us with corrections.